Published in J Virol on July 01, 2005
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell (2009) 3.05
Adaptation of HIV-1 to its human host. Mol Biol Evol (2007) 1.77
HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog (2010) 1.69
Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One (2014) 1.43
Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis (2009) 1.33
The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology (2006) 1.33
Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev (2007) 1.31
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25
Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One (2007) 1.23
Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J Biol Chem (2012) 1.16
Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology (2011) 1.14
Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture. J Clin Microbiol (2006) 1.10
HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol (2013) 1.10
Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. J Clin Virol (2012) 1.10
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS (2008) 1.07
Non-M variants of human immunodeficiency virus type 1. Clin Microbiol Rev (2013) 1.05
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One (2011) 1.04
Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release. Virology (2008) 1.03
The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses. J Virol (2008) 1.02
Mechanisms and factors that influence high frequency retroviral recombination. Viruses (2011) 1.02
Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu. J Virol (2011) 1.01
Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol (2010) 1.01
Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. J Virol (2007) 1.01
Genetic recombination between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct human lentiviruses. J Virol (2007) 1.00
Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. J Mol Biol (2008) 0.95
An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol (2011) 0.93
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol (2011) 0.93
RNA-based mechanisms regulating host-virus interactions. Immunol Rev (2013) 0.92
Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness. Retrovirology (2010) 0.91
HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples. AIDS (2014) 0.91
Determining the frequency and mechanisms of HIV-1 and HIV-2 RNA copackaging by single-virion analysis. J Virol (2011) 0.90
Simian immunodeficiency virus variants that differ in pathogenicity differ in fitness under rapid cell turnover conditions. J Virol (2005) 0.89
Subtype-associated differences in HIV-1 reverse transcription affect the viral replication. Retrovirology (2010) 0.89
Human endogenous retrovirus K Gag coassembles with HIV-1 Gag and reduces the release efficiency and infectivity of HIV-1. J Virol (2012) 0.88
Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function. Retrovirology (2012) 0.87
In vivo fitness associated with high virulence in a vertebrate virus is a complex trait regulated by host entry, replication, and shedding. J Virol (2011) 0.87
Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, Rwanda. PLoS One (2012) 0.85
Similar replicative fitness is shared by the subtype B and unique BF recombinant HIV-1 isolates that dominate the epidemic in Argentina. PLoS One (2014) 0.85
Identification of new splice sites used for generation of rev transcripts in human immunodeficiency virus type 1 subtype C primary isolates. PLoS One (2012) 0.84
Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob Agents Chemother (2013) 0.84
HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts. AIDS (2013) 0.82
Viral factors in non-progression. Front Immunol (2013) 0.82
Clinical, epidemiological and molecular features of the HIV-1 subtype C and recombinant forms that are circulating in the city of São Paulo, Brazil. Virol J (2012) 0.82
Biological signature characteristics of primary isolates from human immunodeficiency virus type 1 group O in ex vivo human tonsil histocultures. J Virol (2009) 0.81
Involvement of a C-terminal motif in the interference of primate lentiviral Vpu proteins with CD1d-mediated antigen presentation. Sci Rep (2015) 0.81
A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay. PLoS One (2011) 0.81
HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. Virus Evol (2016) 0.80
The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission. PLoS One (2016) 0.80
Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage. AIDS Res Ther (2015) 0.80
HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges. Infect Genet Evol (2015) 0.80
Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays. J Clin Microbiol (2010) 0.80
Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa. EBioMedicine (2016) 0.80
Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller. PLoS One (2012) 0.79
The Two-Phase Emergence of Non Pandemic HIV-1 Group O in Cameroon. PLoS Pathog (2015) 0.78
HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One (2012) 0.78
Genetic diversity in HIV-1 subtype C LTR from Brazil and Mozambique generates new transcription factor-binding sites. Viruses (2014) 0.77
Construction of a high titer infectious HIV-1 subtype C proviral clone from South Africa. Viruses (2012) 0.77
HIV-2 genomic RNA accumulates in stress granules in the absence of active translation. Nucleic Acids Res (2014) 0.77
Capsid proteins from human immunodeficiency virus type 1 and simian immunodeficiency virus SIVmac can coassemble into mature cores of infectious viruses. J Virol (2008) 0.77
HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase. Antimicrob Agents Chemother (2014) 0.76
HIV competition dynamics over sexual networks: first comer advantage conserves founder effects. PLoS Comput Biol (2015) 0.76
Hepatitis Viruses B and D and Human Immunodeficiency Virus Infections in Hemodialysis Patients in the South of Iran: Prevalence and Genotypes. Hepat Mon (2016) 0.76
Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains. J Virol (2016) 0.76
Diabetes mellitus and impaired fasting glucose in ART-naïve patients with HIV-1, HIV-2 and HIV-1/2 dual infection in Guinea-Bissau: a cross-sectional study. Trans R Soc Trop Med Hyg (2016) 0.75
HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape. PLoS One (2013) 0.75
Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol (2015) 0.75
HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs. AIDS Res Hum Retroviruses (2016) 0.75
Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity are Consistent with Inter-Subtype Differences in HIV-1 Disease Progression. J Virol (2017) 0.75
A Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV Variants. J Clin Microbiol (2016) 0.75
Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated. Virology (2016) 0.75
Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence. AIDS Res Hum Retroviruses (2014) 0.75
Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test. J Clin Virol (2017) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci (1996) 56.57
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature (1999) 10.97
Timing the ancestor of the HIV-1 pandemic strains. Science (2000) 10.42
RNA virus mutations and fitness for survival. Annu Rev Microbiol (1997) 10.06
AIDS as a zoonosis: scientific and public health implications. Science (2000) 8.28
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol (1999) 3.32
Phylogenetic analysis using PHYLIP. Methods Mol Biol (2000) 3.27
Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science (1994) 3.10
Short-sighted evolution and the virulence of pathogenic microorganisms. Trends Microbiol (1994) 2.91
In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A (2000) 2.78
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol (2000) 2.68
A game-theoretical model of parasite virulence. J Theor Biol (1983) 2.64
Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci U S A (1995) 2.60
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol (1998) 2.50
Slower heterosexual spread of HIV-2 than HIV-1. Lancet (1994) 2.46
SIVcpz in wild chimpanzees. Science (2002) 2.45
Understanding the genetic diversity of HIV-1. AIDS (2000) 2.39
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. J Virol (1995) 2.18
The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc Natl Acad Sci U S A (1999) 2.11
Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. J Clin Invest (1997) 1.98
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol (1999) 1.85
Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol (2004) 1.69
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol (2000) 1.54
Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol (2003) 1.51
Transmission of HIV-2. Lancet Infect Dis (2003) 1.47
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol (2005) 1.42
HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg Infect Dis (2001) 1.41
Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS (2003) 1.40
In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis (1998) 1.40
Human immunodeficiency viruses in the developing world. Adv Virus Res (1999) 1.30
Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis (2004) 1.27
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med (2003) 1.26
Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. J Virol (2000) 1.25
Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. AIDS (1999) 1.19
Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. J Virol (1997) 1.17
Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. J Virol (1997) 1.14
Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. J Virol (1998) 1.04
Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. J Virol (1993) 1.03
Modeling HIV transfer between dendritic cells and T cells: importance of HIV phenotype, dendritic cell-T cell contact and T-cell activation. AIDS (2000) 1.00
Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model. J Virol (2001) 0.98
HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo. AIDS (2000) 0.97
Mapping the determinants of human immunodeficiency virus 2 for infectivity, replication efficiency, and cytopathicity. Proc Natl Acad Sci U S A (1993) 0.94
Analysis of the evolutionary relationships of HIV-1 and SIVcpz sequences using bayesian inference: implications for the origin of HIV-1. Mol Biol Evol (2003) 0.93
Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission. J Virol (1998) 0.92
Sorting out the complexities of HIV-1 fitness. AIDS (2003) 0.90
HIV-1 infection of Langerhans cells in a reconstructed vaginal mucosa. J Infect Dis (2004) 0.88
Intrapatient variability of HIV type 1 group O ANT70 during a 10-year follow-up. AIDS Res Hum Retroviruses (1999) 0.88
The population biology of the interaction between HIV-1 and HIV-2: coexistence or competitive exclusion? AIDS (1996) 0.87
Interpatient genetic variability of HIV-1 group O. AIDS (1999) 0.86
Human schistosomiasis. Lancet (2006) 10.87
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis (2007) 3.80
Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol (2007) 3.05
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol (2004) 2.30
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Multisite evaluation of a point-of-care instrument for CD4(+) T-cell enumeration using venous and finger-prick blood: the PIMA CD4. J Acquir Immune Defic Syndr (2011) 2.08
Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol (2006) 2.06
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS (2005) 1.99
Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis (2010) 1.89
Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol (2004) 1.69
Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis (2006) 1.68
HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Rev (2007) 1.66
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2004) 1.58
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 1.58
A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation. Cell Host Microbe (2013) 1.56
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother (2004) 1.54
Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat (2002) 1.54
Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol (2003) 1.51
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission. Blood (2012) 1.49
Identifying the important HIV-1 recombination breakpoints. PLoS Comput Biol (2008) 1.42
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol (2005) 1.42
CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother (2008) 1.40
Absolute CD4 T-cell counting in resource-poor settings: direct volumetric measurements versus bead-based clinical flow cytometry instruments. J Acquir Immune Defic Syndr (2005) 1.40
Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care (2009) 1.37
Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev (2002) 1.36
Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol (2007) 1.35
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol (2005) 1.34
The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology (2006) 1.33
In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms. J Virol (2002) 1.27
Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol (2002) 1.27
Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods (2006) 1.26
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog (2007) 1.23
Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One (2012) 1.21
Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. J Int Assoc Physicians AIDS Care (Chic) (2009) 1.18
CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr (2006) 1.17
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis (2006) 1.17
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses (2008) 1.16
Family relationship, water contact and occurrence of Buruli ulcer in Benin. PLoS Negl Trop Dis (2010) 1.16
Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol (2006) 1.16
Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J Virol Methods (2003) 1.14
WHO multicenter evaluation of FACSCount CD4 and Pima CD4 T-cell count systems: instrument performance and misclassification of HIV-infected patients. J Acquir Immune Defic Syndr (2014) 1.14
Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol (2007) 1.14
Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr HIV Res (2008) 1.14
Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15--the Amplispot assay. J Immunol Methods (2002) 1.13
Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol (2009) 1.12
Current tests to evaluate HIV-1 coreceptor tropism. Curr Opin HIV AIDS (2009) 1.12
HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J Virol (2012) 1.11
Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS (2006) 1.10
Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol (2010) 1.09
Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.08
PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol (2004) 1.08
Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother (2014) 1.08
Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One (2012) 1.08
MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. PLoS Pathog (2012) 1.07
The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. PLoS One (2013) 1.05
National external quality assessment scheme for lymphocyte immunophenotyping in Belgium. Clin Chem Lab Med (2003) 1.05
Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples. J Clin Microbiol (2008) 1.05
Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Res Hum Retroviruses (2004) 1.05
A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques (2009) 1.03
Influence of sequence identity and unique breakpoints on the frequency of intersubtype HIV-1 recombination. Retrovirology (2006) 1.03
Sequence determinants of breakpoint location during HIV-1 intersubtype recombination. Nucleic Acids Res (2006) 1.02
Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy. AIDS (2003) 1.02
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J Gen Virol (2003) 1.02
Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS (2002) 1.02
Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol (2009) 1.01
Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol (2010) 1.01
Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther (2012) 1.01
The added value of a CD4 count to identify patients eligible for highly active antiretroviral therapy among HIV-positive adults in Cambodia. J Acquir Immune Defic Syndr (2006) 1.00
HIV-1 Entry, Inhibitors, and Resistance. Viruses (2010) 1.00
SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness. J Neurovirol (2006) 1.00
Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother (2006) 0.99
Transcriptome analysis of monocyte-HIV interactions. Retrovirology (2010) 0.98